Immune-Onc Therapeutics, Inc., a Palo Alto, Calif.-based cancer immunotherapy company dedicated to the discovery and development of novel biologic treatments, raised more than $33m in Series B funding.
Backers included Northern Light Venture Capital, Vivo Capital, and the Stanford-StartX Fund.
The company intends to use the funds to advance its pipeline programs.
Led by Charlene Liao, Ph.D., co-founder, president and chief executive officer, and newly added Dr. Adrian Jubb, Chief Medical Officer, and Dr. An Song, Senior Vice President of Development Sciences, Immune-Onc Therapeutics is dedicated to the discovery and development of novel biologic treatments for cancer patients.
The company has a promising pipeline built upon strategic collaborations and research from The University of Texas, Albert Einstein College of Medicine, and Memorial Sloan Kettering Cancer Center.
Both Dr. Jubb and Dr. Song will join the Executive Committee of Immmune-Onc.